Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Metastatic Uveal Melanoma
NCT02517736Phase 2Completed
- Sponsor
- CHU Caen Normandie
- Start
- Feb 2012
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in Uveal melanoma (UM), sponsored by CHU Caen Normandie. Started Feb 2012; status: completed.
02
Drugs
sorafenib
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT02517736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02517736.